NCT06932536View on ClinicalTrials.gov

The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Prescription F1) in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Healthy
Interventions
DRUG

SR750 tablet

Ascending single (30-100 mg) and multiple (30-60 mg twice daily \[b.i.d.\]) doses of SR750 orally

DRUG

Placebo

Ascending single and multiple doses of placebo orally

Trial Locations (1)

Unknown

Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU), Shanghai

All Listed Sponsors
lead

Shanghai SIMR Biotechnology Co., Ltd.

INDUSTRY